Action Eli Lilly - LLY

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

Premium

Dernier

32,18

Prix Achat

31,13

Prix Vente

34,00

Volume échangé

65 286

33,46 Fourchette du Jour 33,46

0,00 Plage de 52 semaines 0,00

Clôture Veille

33,84

Ouverture

33,46

Dernière Transaction

32.18

Dernière heure de transaction

Volume moyen (3 m)

Volume financier

VWAP

Lilly's baricitinib delivered high rates of hair regrowth for adolescents with severe alopecia areata in Phase 3 BRAVE-AA-PEDS study

Lilly's baricitinib delivered high rates of hair regrowth for adolescents with severe alopecia areata in Phase...

Form PRE 14A - Other preliminary proxy statements

Lilly's EBGLYSS® (lebrikizumab-lbkz) single monthly maintenance injection achieved completely clear skin at three years in half of patients with moderate-to-severe atopic dermatitis

Lilly's EBGLYSS® (lebrikizumab-lbkz) single monthly maintenance injection achieved completely clear skin at...

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Lilly to participate in Leerink Partners Global Healthcare Conference

Lilly to participate in Leerink Partners Global Healthcare Conference PR Newswire INDIANAPOLIS, Feb. 28, 2025...

Lilly's Jaypirca (pirtobrutinib) recommended by CHMP for approval in the European Union for adults with relapsed or refractory chronic lymphocytic leukemia (CLL) previously treated with a BTK inhibitor

Lilly's Jaypirca (pirtobrutinib) recommended by CHMP for approval in the European Union for adults with...

Form 4 - Statement of changes in beneficial ownership of securities

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0	0	0	0	0	DR
4	0	0	0	0	0	0	0	DR
12	0	0	0	0	0	0	0	DR
26	0	0	0	0	0	0	0	DR
52	0	0	0	0	0	0	0	DR
156	0	0	0	0	0	0	0	DR
260	0	0	0	0	0	0	0	DR

LLY - Frequently Asked Questions (FAQ)

What is the current Eli Lilly share price?

The current share price of Eli Lilly is $ 32,18

What is the 1 year trading range for Eli Lilly share price?

Eli Lilly has traded in the range of $ 0,00 to $ 0,00 during the past year

Volume
% Gagnants
% Perdants

Symbole	Prix	Vol.
CDMNCanadian Manganese Company Inc	$ 0,025 (25,00%)	173k
IFSSInterfield Global Software Inc	$ 0,065 (8,33%)	1 000
JETGlobal Crossing Airlines Group Inc	$ 0,85 (3,66%)	24,8k
VERSVerses AI Inc	$ 1,31 (3,15%)	326,14k
DEFIValour Inc	$ 3,47 (2,66%)	970,84k
NTDONintendo CDR	10,74 (-7,09%)	1,4k
JET.BGlobal Crossing Airlines Group Inc	$ 0,87 (-5,43%)	10,89k
ZEFIZefiro Methane Corp	$ 0,43 (-4,44%)	49k
HOLDImmutable Holdings Inc	$ 0,125 (-3,85%)	44,45k
HNDAHonda CDR	9,79 (-1,21%)	500
DEFIValour Inc	$ 3,47 (2,66%)	970,84k
MLMMcfarlane Lake Mining Limited	$ 0,05 (0,00%)	631k
FCGSFidelity Global Small Cap Opportunities Fund	$ 14,98 (0,00%)	416,29k
VERSVerses AI Inc	$ 1,31 (3,15%)	326,14k
ALGOLight AI Inc	0,64 (0,00%)	305,78k

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Eli Lilly and Company (LLY)

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

Statistiques et détails clés

LLY Dernières nouvelles

Lilly's baricitinib delivered high rates of hair regrowth for adolescents with severe alopecia areata in Phase 3 BRAVE-AA-PEDS study

Form PRE 14A - Other preliminary proxy statements

Lilly's EBGLYSS® (lebrikizumab-lbkz) single monthly maintenance injection achieved completely clear skin at three years in half of patients with moderate-to-severe atopic dermatitis

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Lilly to participate in Leerink Partners Global Healthcare Conference

Lilly's Jaypirca (pirtobrutinib) recommended by CHMP for approval in the European Union for adults with relapsed or refractory chronic lymphocytic leukemia (CLL) previously treated with a BTK inhibitor

Form 4 - Statement of changes in beneficial ownership of securities

Lilly's baricitinib delivered high rates of hair regrowth for adolescents with severe alopecia areata in Phase 3 BRAVE-AA-PEDS study

Form PRE 14A - Other preliminary proxy statements

Lilly's EBGLYSS® (lebrikizumab-lbkz) single monthly maintenance injection achieved completely clear skin at three years in half of patients with moderate-to-severe atopic dermatitis

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Lilly to participate in Leerink Partners Global Healthcare Conference

LLY - Frequently Asked Questions (FAQ)

Moteurs

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0	0	0	0	0	DR
4	0	0	0	0	0	0	0	DR
12	0	0	0	0	0	0	0	DR
26	0	0	0	0	0	0	0	DR
52	0	0	0	0	0	0	0	DR
156	0	0	0	0	0	0	0	DR
260	0	0	0	0	0	0	0	DR

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0	0	0	0	0	DR
4	0	0	0	0	0	0	0	DR
12	0	0	0	0	0	0	0	DR
26	0	0	0	0	0	0	0	DR
52	0	0	0	0	0	0	0	DR
156	0	0	0	0	0	0	0	DR
260	0	0	0	0	0	0	0	DR

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Eli Lilly and Company (LLY) Cours

Eli Lilly and Company (LLY)

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

Statistiques et détails clés

LLY Dernières nouvelles

Lilly's baricitinib delivered high rates of hair regrowth for adolescents with severe alopecia areata in Phase 3 BRAVE-AA-PEDS study

Form PRE 14A - Other preliminary proxy statements

Lilly's EBGLYSS® (lebrikizumab-lbkz) single monthly maintenance injection achieved completely clear skin at three years in half of patients with moderate-to-severe atopic dermatitis

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Lilly to participate in Leerink Partners Global Healthcare Conference

Lilly's Jaypirca (pirtobrutinib) recommended by CHMP for approval in the European Union for adults with relapsed or refractory chronic lymphocytic leukemia (CLL) previously treated with a BTK inhibitor

Form 4 - Statement of changes in beneficial ownership of securities

Lilly's baricitinib delivered high rates of hair regrowth for adolescents with severe alopecia areata in Phase 3 BRAVE-AA-PEDS study

Form PRE 14A - Other preliminary proxy statements

Lilly's EBGLYSS® (lebrikizumab-lbkz) single monthly maintenance injection achieved completely clear skin at three years in half of patients with moderate-to-severe atopic dermatitis

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Lilly to participate in Leerink Partners Global Healthcare Conference

LLY - Frequently Asked Questions (FAQ)

Moteurs

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Supprimer les publicités

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0	0	0	0	0	DR
4	0	0	0	0	0	0	0	DR
12	0	0	0	0	0	0	0	DR
26	0	0	0	0	0	0	0	DR
52	0	0	0	0	0	0	0	DR
156	0	0	0	0	0	0	0	DR
260	0	0	0	0	0	0	0	DR